1.Combination modality therapy for stages Ⅰ and Ⅱ primary gastrointestinal non-Hodgkin's lymphoma
Chinese Journal of Radiation Oncology 1992;0(01):-
Purpose: To detect the prognostic factors for early primary gastrointestinal non-Hodgkin's lymphoma treated by various treatments.Materials and Methods:32 aptients with stages Ⅰ and Ⅱ primary gastrointestinal non-Hodgkin's lymphoma treated from January, 1970 to November, 1987 were retrospectively reviewed. The primary sites of cancers were: 15 in stomach, 10 in ileocecal region, 4 in large bowel and 3 in small bowel. 24 patients underwent curative resection, 7 patients underwent incomplete resection and 1,unresectable. Postoperative radiotherapy was given to all patients.Among them, 14 patients received radiotherapy plus chemotherapy.Results: The overall 5-year survival rate was 59.4%(19/32).Conclusion: The main prognostic factors are the site of primary tumor, depth of invasion, stages and modalities of managements.Sex, age, and histologic does not influence the survivals.
2.A study on ~(89)Strontium radionuclide therapy for pain-relief and rehabilitation of senile patients with bone metastatic cancer
Chinese Journal of Physical Medicine and Rehabilitation 2003;0(12):-
Objective To evaluate the efficacy and the toxicity of 89Strontium( 89 Sr) radionuclide therapy for the senile patients with bone metastatic cancer, and study the effects of 89 Sr on the image of bone metastasis, and to assess the utility of 89 Sr treatment for the senile patients in rehabilitation. Methods The effect on pain relief and the side effects of 27 senile patients with bone metastatic cancer were observed. The bone SPECT image was compared between those before and after the treatment, blood routine and blood biochemistry was tested. Results The total response rate was 70.4%, while the response rate of bone metastasis originated from prostatic cancer and breast cancer was 78.9%. A few metastasis sites in bone image disappeared or the concentration in the image became weak. A mild reversible harm to bone marrow function was the main side effect. 89 Sr had a little effect on blood biochemistry. Conclusion Radionuclide therapy with 89 Sr was an effective and well-tolerated method for the senile patients with bone metastatic cancer, which was a novel approach for pain-relief and rehabilitation of senile patients with bone metastatic cancer.
3.Determination of carboplatin dose by area under the curve in combination chemotherapy for senile non-small cell lung cancer.
Tiejun, YIN ; Qingqing, LIU ; Changyao, HU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2007;27(6):710-2
To preliminarily determine the appropriate dosage of carboplatin (CBP) at AUC of 5 mg.Ml(-1).min(-1) in the combination chemotherapy for Chinese senile patients with non-small cell lung cancer (NSCLC). Thirty-five Chinese senile patients with NSCLC in advanced stage (III/IV) were given 96 cycles of combination chemotherapy. Chemotherapy schedules included Taxol+CBP, Gemzar+CBP and NVB+CBP. The dose of CBP was at 5 mg.mL(-1).min(-1) of area under the concentration-time curve (AUC). Side effects and quality of life were observed before and after the chemotherapy. Myelosuppression was severe and commonly observed. Grade 3/4 of granulocytopenia was found in 47.9% (46/96) of the patients and grade 3/4 of thrombocytopenia was noted in 28.1% (27/96) of the subjects. However, other side effects were slight. The mean score of quality of life (QOL), according to the criteria of QOL for Chinese cancer patients had reduced 6.8. At 5 mg.mL(-1).min(-1) by AUC, the hematological toxicity of CBP was severe and it had some negative effects on the QOL. The administration of CBP at 5 mg.mL(-1).min(-1) by AUC may be too high for Chinese senile patients with non-small cell lung cancer.
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Area Under Curve
;
Carboplatin/*administration & dosage
;
Carboplatin/adverse effects
;
Carcinoma, Non-Small-Cell Lung/*drug therapy
;
Lung Neoplasms/*drug therapy
4.Iscom matrix enhances the immunogenicity of hepatitis B virus surface antigen containing Pres epitopes
Changyao TAN ; Lin YE ; Liming JIANG ; Pengyan ZHANG ; Bo HU ; Morein BROR
Chinese Journal of Microbiology and Immunology 2011;31(7):643-646
Objective To investigate the effect of Iscom matrix on the immunogenicity of recombinant hepatitis B surface antigen containing PreS epitopes(SS1S2). Methods SS1S2+ Al(OH)3 and SS1S2+Iscom vaccines were made by combining purified SS1S2 antigen with Al( OH)3 adjuvant or Iscom matrix.Groups of BALB/c mice were injected i. m or s. c by either of the two vaccines at day 0 and day 14. Half of the mice were sacrificed and sera were taken and spleen cells separated from the mice 14 days after each injection. Anti-S, anti-PreS1, and anti-PreS2 antibody titers were measured, and total IgG1 and IgG2a titers were further detected for each serum sample. IFN-γ ELISPOT assay was performed to detect IFN-γsecreting cells from the pooled spleen cells for each vaccine group. Results The seroconversion rates and geometric mean titers(GMTs) and the numbers of IFN-γ secreting cells were approximately at the same level for the differently formulated vaccines after the first injection except that the ratio of IgG2a to IgG1 in the Iscom group was higher than the Al(OH)3 group. After boost injection, the GMTs of total IgG rise slightly in the Al(OH)3 group but significantly in the Iscom group. The IgG2a to IgG1 ratio in the Iscom group kept balanced while dropped further in the Al(OH)3 group. The number of specific IFN-γsecreting cells triggered by the Iscom vaccine exceeded significantly the number of Al( OH)3 vaccine, showinga stronger cellular response. Conclusion The results in this study shows that Iscom matrix is more potent in enhancing the immunogenicity of recombinant hepatitis B virus surface antigen containing PreS epitopes than Al( OH)3 adjuvant.
5.Determination of Carboplatin Dose by Area Under the Curve in Combination Chemotherapy for Senile Non-small Cell Lung Cancer
Tiejun YIN ; Qingqing LIU ; Changyao HU ; Mengtao LIU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2007;27(6):710-712
To preliminarily determine the appropriate dosage of carboplatin (CBP) at AUC of 5 mg·Ml-1·min-1 in the combination chemotherapy for Chinese senile patients with non-small cell lung cancer (NSCLC). Thirty-five Chinese senile patients with NSCLC in advanced stage (Ⅲ/Ⅳ) were given 96 cycles of combination chemotherapy. Chemotherapy schedules included Taxol+CBE Gemzar+CBP and NVB+CBP. The dose of CBP was at 5 mg·mL-1·min-1 of area under the concen- tration-time curve (AUC). Side effects and quality of life were observed before and after the chemo- therapy. Myelosuppression was severe and commonly observed. Grade 3/4 of granuiocytopenia was found in 47.9% (46/96) of the patients and grade 3/4 of thrombocytopenia was noted in 28.1% (27/96) of the subjects. However, other side effects were slight. The mean score of quality of life (QOL), ac- cording to the criteria of QOL for Chinese cancer patients had reduced 6.8. At 5 mg·mL-1·min-1 by AUC, the hematological toxicity of CBP was severe and it had some negative effects on the QOL. The administration of CBP at 5 mg·mL-1·min-1 by AUC may be too high for Chinese senile patients with non-small cell lung cancer.